FDA Extends Review Timeline for Aldeyra's Reproxalap Dry Eye Treatment to March 2026
核心洞察
The FDA has extended the PDUFA target action date for Aldeyra Therapeutics' reproxalap New Drug Application for dry eye disease (搜索) treatment from December 16, 2025, to March 16, 2026.
The extension was triggered by the FDA's request for a Clinical Study Report from a field trial that supported reproxalap's activity but failed to meet its primary endpoint of symptom improvement.
The FDA indicated that if no major deficiencies are identified during the extended review, it plans to communicate proposed labeling requests by February 16, 2026.
Aldeyra Therapeutics announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target action date for reproxalap's New Drug Application for dry eye disease (搜索) treatment from December 16, 2025, to March 16, 2026. The extension follows the FDA's request for additional clinical documentation during a December 12, 2025 meeting.
Regulatory Timeline and FDA Request
The reproxalap NDA was originally submitted on June 16, 2025, and accepted for review as a "complete class 2 response" by the FDA on July 16, 2025. During the December 12 meeting, the FDA specifically requested submission of the Clinical Study Report (CSR) for reproxalap's dry eye disease (搜索) field trial, which had top-line results announced on May 5, 2025.
The field trial, while supportive of reproxalap's activity relative to vehicle, did not meet the primary endpoint of improvement in dry eye symptoms compared to the vehicle control. The CSR, which had been previously submitted to the Investigational New Drug file for reproxalap, was submitted to the NDA on the same day as the meeting and was considered a major amendment by the FDA.
FDA Review Status and Next Steps
At the December 12 meeting, the FDA made no other requests and did not identify any other specific issues with the NDA review. The safety data from the field trial had been previously submitted to the NDA on August 21, 2025, per the FDA's earlier request during the NDA review process.
In early December, the FDA shared with Aldeyra a draft of the prospective label, and Aldeyra has submitted a response. The FDA notified Aldeyra that if no major deficiencies are identified during the extended review, the agency plans to communicate proposed labeling requests and, if necessary, any anticipated postmarketing requirements by February 16, 2026.
About Reproxalap and Aldeyra's Pipeline
Reproxalap is a RASP (搜索) (reactive aldehyde species) modulator being developed for the potential treatment of dry eye disease (搜索) and allergic conjunctivitis (搜索). Aldeyra Therapeutics is a biotechnology company focused on discovering innovative therapies designed to treat immune-mediated diseases through modulating protein systems rather than directly inhibiting or activating single protein targets.
The company's approach aims to optimize multiple pathways simultaneously while minimizing toxicity. Beyond reproxalap, Aldeyra's pipeline includes other RASP (搜索) modulators ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases, as well as ADX-2191, a novel formulation of intravitreal methotrexate for primary vitreoretinal lymphoma (搜索) and retinitis pigmentosa (搜索).
Market Response
Following the announcement, Aldeyra's stock (NASDAQ: ALDX) closed Monday's regular trading at $3.99, down $0.55 or 12.11%. In after-hours trading, the stock declined further to $3.32, representing an additional drop of $0.67 or 16.79%.